Stand Up To Cancer (SU2C) is a groundbreaking initiative created to accelerate innovative cancer research that will get new therapies to patients quickly and save lives now. SU2C brings together the best and the brightest researchers and encourages collaboration instead of competition among the entire cancer community. By galvanizing the entertainment industry, SU2C creates awareness and builds broad public support for this effort.
In December of 2012, CRI and SU2C, along with SU2C's scientific partner, the American Association for Cancer Research, announced that the Cancer Immunology Translational Research Dream Team will receive $10 million over three years. The award will allow the Dream Team to focus on developing cancer treatments based on immunological checkpoint blockade combined with adoptive T cell transfer, two highly promising approaches to cancer immunotherapy. Read our joint news release announcing the winning Dream Team members and projects, or read a detailed description to learn more.
Stay tuned for announcements about this exciting program by following us on Twitter at @CancerResearch and search "#su2c-cri".
Dream Team Timeline
June 13, 2013 - CRI and SU2C launch a new print public service announcement featuring NCIS star Mark Harmon. The PSA, entitled “I Am My Own Secret Weapon,” is designed to increase awareness about cancer immunotherapy, which mobilizes our immune systems to fight cancer. Read the joint news release here.
December 12, 2012 - CRI and SU2C, along with SU2C's scientific partner, the American Association for Cancer Research, announce the winners of the Cancer Immunology Translational Research Dream Team award. Read our joint news release announcing the winning Dream Team members and projects.
September 7, 2012 - The SU2C-CRI partnership is mentioned during SU2C’s star-studded hour-long, multi-network television telecast, which had 9 million live viewers worldwide.
March 7, 2012 - SU2C and the Cancer Research Institute announce a powerful partnership to combine the strengths of both organizations to accelerate the application of new immune system-based diagnostic or therapeutic agents to the clinic within 2-3 years. Through a jointly funded grant of $6 million, CRI and SU2C will convene a multi-institutional, multi-disciplinary Dream Team of expert investigators focused on delivering near-term patient benefit through collaborative investigation. Read our March 2012 news release announcing the partnership.